Business - STAT

Biotech

A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know

By Adam Feuerstein

Business

A ‘semi-wartime’ effort: Thermo Fisher COO on adapting the business to a Covid-19 world

By Elizabeth Cooney

Biotech

Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug

By Adam Feuerstein

Biotech

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

By Elizabeth Cooney

Business

‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi

By Elizabeth Cooney

Biotech

Startup Spotlight: Aiming to speed precision cancer therapies to children

By Elizabeth Cooney

Special Report

Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO

By Erin Brodwin and Casey Ross

Business

Gawande says leaving Haven CEO job will allow him to focus on Covid-19

By Casey Ross

Business

Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?

By Casey Ross and Erin Brodwin

Special Report

With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake

By Nicholas Florko and Damian Garde

Business

Gilead’s remdesivir has seen success against the coronavirus. Now the company has to make enough to supply the world

By Andrew Joseph

Business

Patients, drug makers grapple with how to continue cancer trials during the coronavirus

By Andrew Joseph

Biotech

Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis

By Adam Feuerstein

Biotech

Digital event: Combating Covid-19

By Matthew Herper

Business

Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know

By Andrew Joseph, Adam Feuerstein, Damian Garde, and Matthew Herper

Biotech

Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer

By Adam Feuerstein

Business

Boston Scientific cutting hours and pay as revenue drops

By Jonathan Saltzman — Boston Globe

Biotech

The biotech scorecard for the second quarter: 18 stock-moving events to watch

By Adam Feuerstein

Biotech

Amarin loses legal fight over heart drug patent; shares sink

By Adam Feuerstein

Health

‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19

By Elizabeth Cooney

Biotech

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

By Adam Feuerstein and Matthew Herper

Biotech

Drug makers grounding salespeople as coronavirus impact on business spreads

By Adam Feuerstein

Biotech

How one company made $208 million on an untested coronavirus vaccine

By Damian Garde and Adam Feuerstein

Business

The Engine at MIT is revving up the potential of ‘tough tech’

By Scott Kirsner — Boston Globe

Biotech

Thermo Fisher buys Dutch diagnostics company for $11.5 billion

By Jonathan Saltzman — Boston Globe

The biotech scorecard for the third quarter: 14 stock-moving events to watch

FDA rejects Intercept Pharma’s drug for NASH

Zogenix wins approval for new drug to treat rare type of childhood epilepsy

After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows

A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know

A ‘semi-wartime’ effort: Thermo Fisher COO on adapting the business to a Covid-19 world

Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi

Startup Spotlight: Aiming to speed precision cancer therapies to children

Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO

Gawande says leaving Haven CEO job will allow him to focus on Covid-19

Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?

With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake

Gilead’s remdesivir has seen success against the coronavirus. Now the company has to make enough to supply the world

Patients, drug makers grapple with how to continue cancer trials during the coronavirus

Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis

Digital event: Combating Covid-19

Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know

Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer

Boston Scientific cutting hours and pay as revenue drops

The biotech scorecard for the second quarter: 18 stock-moving events to watch

Amarin loses legal fight over heart drug patent; shares sink

‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

Drug makers grounding salespeople as coronavirus impact on business spreads

How one company made $208 million on an untested coronavirus vaccine

The Engine at MIT is revving up the potential of ‘tough tech’

Thermo Fisher buys Dutch diagnostics company for $11.5 billion